STOCK TITAN

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Iterum Therapeutics (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing next-generation oral antibiotics for multi-drug resistant pathogens in community settings, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Corey Fishman will engage in a Fireside Chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, on October 16, 2024, at 10:00 a.m. ET.

The summit is scheduled from October 15 – 17, 2024, and will be live-streamed on M-Vest. Interested parties can register and access the fireside chat through the provided link: https://m-vest.com/events/healthcare-10152024.

Iterum Therapeutics (Nasdaq: ITRM), una società farmaceutica in fase clinica che sviluppa antibiotici orali di nuova generazione per patogeni multi-resistenti in contesti comunitari, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il CEO Corey Fishman parteciperà a una conversazione informale con Jason McCarthy, Ph.D., Senior Managing Director e Responsabile della Ricerca Biotecnologica presso Maxim Group, il 16 ottobre 2024, alle 10:00 a.m. ET.

Il summit è in programma dal 15 al 17 ottobre 2024 e sarà trasmesso in diretta su M-Vest. Le parti interessate possono registrarsi e accedere alla conversazione informale tramite il link fornito: https://m-vest.com/events/healthcare-10152024.

Iterum Therapeutics (Nasdaq: ITRM), una compañía farmacéutica en etapa clínica que desarrolla antibióticos orales de próxima generación para patógenos multirresistentes en entornos comunitarios, ha anunciado su participación en la 2024 Maxim Healthcare Virtual Summit. El CEO Corey Fishman participará en una charla informal con Jason McCarthy, Ph.D., Director General Sénior y Jefe de Investigación Biotecnológica en Maxim Group, el 16 de octubre de 2024, a las 10:00 a.m. ET.

La cumbre se llevará a cabo del 15 al 17 de octubre de 2024 y se transmitirá en vivo por M-Vest. Las partes interesadas pueden registrarse y acceder a la charla informal a través del enlace proporcionado: https://m-vest.com/events/healthcare-10152024.

Iterum Therapeutics (Nasdaq: ITRM)는 커뮤니티 환경에서 다제내성 병원체를 위한 차세대 경구 항생제를 개발하는 임상 단계 제약 회사로, 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. CEO Corey FishmanJason McCarthy, Ph.D., Maxim Group의 생명공학 연구책임자와 함께 2024년 10월 16일 오전 10시(동부 표준시)에 대화형 채팅에 참여할 예정입니다.

이 서밋은 2024년 10월 15일부터 17일까지 예정되어 있으며 M-Vest에서 생중계됩니다. 관심 있는 분들은 제공된 링크를 통해 등록하고 대화형 채팅에 접근할 수 있습니다: https://m-vest.com/events/healthcare-10152024.

Iterum Therapeutics (Nasdaq: ITRM), une entreprise pharmaceutique en phase clinique développant des antibiotiques oraux de nouvelle génération pour les agents pathogènes multirésistants dans les milieux communautaires, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le PDG Corey Fishman participera à une discussion informelle avec Jason McCarthy, Ph.D., Directeur Général Senior et Responsable de la Recherche en Biotechnologie chez Maxim Group, le 16 octobre 2024 à 10h00 ET.

Le sommet est prévu du 15 au 17 octobre 2024 et sera diffusé en direct sur M-Vest. Les personnes intéressées peuvent s'inscrire et accéder à la discussion informelle via le lien fourni : https://m-vest.com/events/healthcare-10152024.

Iterum Therapeutics (Nasdaq: ITRM), ein pharmazeutisches Unternehmen in der klinischen Phase, das Zukunftsantibiotika zur oralen Einnahme für multiresistente Krankheitserreger in Gemeinschaftssettings entwickelt, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt gegeben. CEO Corey Fishman wird am 16. Oktober 2024 um 10:00 Uhr ET in einem Fireside Chat mit Jason McCarthy, Ph.D., Senior Managing Director und Leiter der Biotechnologieforschung bei Maxim Group, teilnehmen.

Der Gipfel findet vom 15. bis 17. Oktober 2024 statt und wird live auf M-Vest gestreamt. Interessierte können sich anmelden und über den bereitgestellten Link auf das Fireside Chat zugreifen: https://m-vest.com/events/healthcare-10152024.

Positive
  • None.
Negative
  • None.

DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced it will participate in the 2024 Maxim Healthcare Virtual Summit. Corey Fishman, CEO of Iterum, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 10:00 a.m. ET on October 16, 2024.

The Maxim Healthcare Summit will take place from October 15 – 17, 2024. This conference will be live on M-Vest. To access, register and watch the fireside chat here: https://m-vest.com/events/healthcare-10152024.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.

Investor Contact:
Judy Matthews 
Chief Financial Officer
312-778-6073
IR@iterumtx.com


FAQ

When is Iterum Therapeutics (ITRM) participating in the 2024 Maxim Healthcare Virtual Summit?

Iterum Therapeutics (ITRM) is participating in the 2024 Maxim Healthcare Virtual Summit from October 15 to 17, 2024. CEO Corey Fishman will join a Fireside Chat on October 16, 2024, at 10:00 a.m. ET.

Who will represent Iterum Therapeutics (ITRM) at the 2024 Maxim Healthcare Virtual Summit?

Corey Fishman, CEO of Iterum Therapeutics (ITRM), will represent the company at the 2024 Maxim Healthcare Virtual Summit.

How can I access the Iterum Therapeutics (ITRM) Fireside Chat at the 2024 Maxim Healthcare Virtual Summit?

You can access the Iterum Therapeutics (ITRM) Fireside Chat by registering and watching it live on M-Vest. The registration link is https://m-vest.com/events/healthcare-10152024.

What is the focus of Iterum Therapeutics (ITRM) as mentioned in the press release?

Iterum Therapeutics (ITRM) is a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings.

Iterum Therapeutics plc Ordinary Share

NASDAQ:ITRM

ITRM Rankings

ITRM Latest News

ITRM Stock Data

56.96M
27.10M
1.81%
8.99%
11.15%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2